Contineum Therapeutics (CTNM) Profit After Tax (2023 - 2026)

Contineum Therapeutics' Profit After Tax history runs 4 years deep, the most recent figure standing at -$15.5 million for Q2 2026.

• In Q2 2026, Profit After Tax rose 3.67% year-over-year to -$15.5 million; the TTM figure through Jun 2026 stood at -$57.9 million (down 1.73% YoY), while the FY2025 annual figure was -$60.0 million, down 41.86% from the prior year.
• Profit After Tax for Q2 2026 stood at -$15.5 million, down from -$14.5 million in the prior quarter.
• The five-year high for Profit After Tax was $41.6 million in Q2 2023, with the low at -$16.1 million in Q2 2025.
• The 4-year median for Profit After Tax is -$11.5 million (2024), against an average of -$7.8 million.
• The sharpest annual moves came in 2024 and 2026: Profit After Tax tumbled 121.68% in 2024, then advanced 9.59% in 2026.
• Contineum Therapeutics' Profit After Tax stood at -$7.6 million in 2023, then sank by 92.51% to -$14.6 million in 2024, then fell by 3.94% to -$15.2 million in 2025, then decreased by 1.95% to -$15.5 million in 2026.
• Business Quant data shows CTNM's Profit After Tax at -$15.5 million in Q2 2026, -$14.5 million in Q1 2026, and -$15.2 million in Q4 2025.